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Summary
 
The activity of interleukin (IL)-9 on B cells was analyzed in vivo using transgenic mice that
constitutively express this cytokine. These mice show an increase in both baseline and antigen-
specific immunoglobulin concentrations for all isotypes tested. Analysis of B cell populations
showed a specific expansion of Mac-1
 
1
 
 B-1 cells in the peritoneal and pleuropericardial cavi-
ties, and in the blood of IL-9 transgenic mice. In normal mice, the IL-9 receptor was found to
be expressed by CD5
 
1
 
 as well as CD5
 
2
 
 B-1 cells, and repeated injections of IL-9 resulted in
accumulation of B-1 cells in the peritoneal cavity, as observed in transgenic animals. Unlike
other mouse models, such as IL-5 transgenic mice, in which expansion of the B-1 population is
associated with high levels of autoantibodies, IL-9 did not stimulate the production of autoan-
tibodies in vivo, and most of the expanded cells were found to belong to the B-1b subset
(IgM
 
1
 
Mac-1
 
1
 
CD5
 
2
 
). In addition, we found that these IL-9–expanded B-1b cells do not share
the well-documented antibromelain-treated red blood cell specificity of CD5
 
1
 
 B-1a cells. The
increase of antigen-specific antibody concentration in immunized mice suggests that these B-1
cells are directly or indirectly involved in antibody responses in IL-9 transgenic mice.
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I
 
nterleukin (IL)-9 is a Th2 cytokine originally identified as a
mouse T cell growth factor. Additional in vitro targets in-
clude mast cells, B cells, and hematopoietic progenitors (1),
and in vivo studies have pointed to a role for IL-9 hyperex-
pression in allergies and lymphoma development. A link be-
tween dysregulated IL-9 production and lymphoid malignan-
cies has been suggested by the observation of constitutive
IL-9 expression in lymph nodes from patients with Hodgkin’s
disease and large cell anaplastic lymphomas (2). Moreover,
mice overexpressing IL-9 show a high susceptibility to the
development of T cell lymphomas (3), which further supports
the view that IL-9 is a tumor-promoting factor.
The implication of IL-9 in the complex pathogenesis of
asthma was also proposed recently. In humans, the IL-9
gene is located on chromosome 5q31-q33, in a region for
which a linkage has been demonstrated with asthma or its
risk factors (4, 5). Interestingly, a linkage for asthma and
broncho-hyperresponsiveness has also been reported for
the long-arm pseudoautosomal regions of the X and Y
chromosomes, where the IL-9 receptor gene is located (6).
In the mouse, in addition to a genetic linkage, comparison
between bronchial hyporesponsive C57BL/6 and hyperre-
sponsive DBA/2 mice has pointed to significant differences
in IL-9 production (7). In line with these observations, IL-9
transgenic mice show a broncho-hyperresponsiveness as
well as mast cell and eosinophil lung accumulation (8, 9).
A role for IL-9 in Ig production has also been suggested
based on in vitro experiments (10–12). Most of these ex-
perimental models focused on IgE production, and it is un-
clear whether or not IL-9 has a preferential effect on this
class of Ig. The mechanism of action of IL-9 also remains
unclear. Surprisingly, although no detectable IL-9 binding
has been found on normal mouse B cells (13), IL-9 appears
to be active on purified B cells (10).
In this report, we describe a significant increase of serum
Ig in IL-9 transgenic mice, associated with an expansion of B
lymphocytes from the B-1 subset (Mac-1
 
1
 
IgM
 
1
 
). In normal
mice, this population represents only 1% of total B cells and
is limited to the peritoneal and pleuropericardial cavities. In
IL-9 transgenic mice, B-1 cells not only accumulate in
these cavities, but are also detected in the blood. Further
analysis showed that the IL-9 receptor is expressed by both
B-1a and B-1b cells. However, most of the in vivo–
expanded B cells belong to the B-1b subpopulation (IgM
 
1
 
Mac-1
 
1
 
CD5
 
2
 
) and do not have the antibromelain-treated
RBC specificity described for the B-1 lymphocytes. 
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Materials and Methods
 
Transgenic and Other Strains of Mice.
 
Transgenic mice overex-
pressing the IL-9 gene were generated in the FVB/N back-
ground using a construct consisting of an IL-9 genomic fragment
linked to the promoter of the murine pim-1 gene, including the
TATA box and the cap site, followed by two copies of the E
 
m
 
enhancer and one copy of the mMLV LTR, as described previ-
ously (3). Although this construct should be preferentially ex-
pressed in the lymphoid lineage, transgenic animals express large
amounts of IL-9 message in all organs, and high levels of biologi-
cally active IL-9 (
 
6 
 
1 
 
m
 
g/ml) have been detected in the serum of
transgenic but not control mice. We used females of 8–12 wk
of age, except in the kinetics experiment, where we used animals
of 3, 6, 12, 25, or 48 wk, or older than 18 mo. Mice were main-
tained in a specific pathogen–free environment. Five indepen-
dent transgene-positive lines (Tg5, Tg54, Tg83, Tg25, and
Tg95) were obtained. For most experiments, the results obtained
with the Tg5 line are shown, as these mice give results that are
representative for the other IL-9 transgenic lines.
Animals carrying the IL-9 transgene and deficient in IL-5 were
obtained by crossing IL-5 knockout C57BL/6 mice (14) and Tg5
or Tg54 mice. F1 mice were backcrossed with IL-5–deficient
mice. 50% of the F2 mice were homozygous for the targeted
IL-5 gene, and 50% of these expressed the IL-9 transgene. All of
the IL-9 transgenic F2 mice expressed similar IL-9 concentrations
in serum (mean of 0.2 
 
m
 
g/ml). Normal 8-wk-old C57BL/6 mice
were used for the IL-9 injection experiment.
 
In Vivo Treatments.
 
Groups of five mice (FVB/N or C57BL/6)
received recombinant murine IL-9 (1 
 
m
 
g/d i.p.), which was
produced and purified in our laboratory as described previously
(13). Control groups of mice received the same volume of buffer
(PBS plus 1% mouse serum) used for the cytokine injection. The
treatment was performed for 3, 7, 14, or 21 consecutive days. For
the LPS injection, 10 FVB and Tg5 females were injected with
50 
 
m
 
g i.p. LPS (Re 595 from 
 
Salmonella minnesota
 
; Sigma Chemi-
cal Co.) 3 times, at 1-wk intervals, and blood samples were col-
lected 1 wk after the last injection.
 
Cell Preparations and FACS
 
®
 
 Analysis.
 
Peritoneal and pleural
cells were obtained by washing the cavities with 3–5 ml of NaCl
0.9% or medium containing 20 U/ml heparin (Leo Pharmaceuti-
cals). Heparinized blood samples were centrifuged on a Ficoll
layer and incubated for 5 min in 0.15 M NH
 
4
 
Cl in order to lyse
the RBCs. Spleen cells were treated similarly, to remove RBCs.
Double labeling of cells was performed with biotinylated rat
mAbs against Mac-1 (M1/70, rat IgG1) followed by PE-conju-
gated streptavidin (Becton Dickinson) and FITC-conjugated
anti-IgM (LOMM9; provided by H. Bazin, University of Louvain)
or FITC-conjugated anti–Mac-1 (Cedarlane Labs., Ltd.) plus PE-
conjugated anti-CD5 (PharMingen). Three-color analysis was
also performed with FITC-conjugated anti-IgM, PE-conjugated
anti-CD5, and biotinylated anti–Mac-1 followed by RED670
(GIBCO BRL)–conjugated streptavidin. Negative controls for
double labeling were cells incubated with the respective single la-
beling. PE-conjugated IgG
 
2a
 
 isotype (PharMingen) was used as
control of specificity of CD5 staining. After staining, cells were
fixed in paraformaldehyde 1.25%, and fluorescence intensity was
measured on 10
 
4
 
 cells/sample on a FACScan™ apparatus (Becton
Dickinson).
An IL-9–Ig fusion protein was produced as follows. The mu-
rine IL-9 cDNA was amplified by PCR using a mutated antisense
primer that introduced a BclI restriction site just before the stop
codon: 5
 
9
 
-TCGGCTGATCAGCCTTTGCATCTCTGT-3
 
9
 
. The
region comprising the hinge, CH2, and CH3 domains of the
 
murine IgG3 isotype heavy chain was amplified by PCR using
cDNA from the IgG
 
3
 
 anti-TNP hybridoma C3110 as a template
with the following primers (15): 5
 
9
 
-AAGACTGAGTTGAT-
CAAGAGAATCGAGCCTAGA-3
 
9
 
 (sense), and 5
 
9
 
-AATGTCTA-
GATGCTGTTCTCATTTACC-3
 
9
 
 (antisense) containing BclI
and XbaI sites for cloning. After amplification, both PCR prod-
ucts were digested with the appropriate restriction enzymes and
cloned into the pCDNA/Amp plasmid (Invitrogen). Clones with
the correct insert were transiently transfected into COS7 cells,
and supernatants were collected after 3 d. For FACS
 
®
 
 staining,
cells were incubated with 10% COS cell supernatant as the first
step and with PE- or FITC-labeled polyclonal anti-IgG
 
3
 
 (South-
ern Laboratories) as the second step. To assess the specificity of
the IL-9 receptor staining, we performed the labeling in the pres-
ence or absence of an excess of free IL-9 (10
 
3
 
 U).
 
Spontaneous and Specific Ig Secretion.
 
Groups of 20 animals of
8–12 wk were used for measuring antibody secretion. For anti-
gen-specific responses, 20 females were immunized with 100 
 
m
 
g
i.p. of KLH or TNP-Ficoll in PBS buffer, and boosted 15 d later
with the same dose of antigen always without adjuvant. Sera were
obtained 15 d after the first immunization and 15 d after the
boost. Sera were conserved at 4
 
8
 
C with azide (
 
6
 
10 mM) before
antibody measurements.
Antigen-specific antibody measurements were performed as
described (16). Microtiter plates (Immunoplates; Nunc, Inc.)
were coated with the antigen (20 
 
m
 
g/ml KLH [Calbiochem-Beh-
ring Corp.] or 10 
 
m
 
g/ml TNP-Ficoll) in glycine (20 mM)–buf-
fered NaCl (30 mM), pH 9.2, and incubated overnight at room
temperature. After washing in 0.15 M NaCl plus Triton 0.01%, se-
rial dilutions of samples were added and plates were incubated for
2–3 h at 37
 
8
 
C. After incubation, plates were washed as before, then
soaked for 7 min in saline plus NP-40 1% (Fluka AG) before fur-
ther incubation. Bound Ig was detected using rabbit antibodies
specific for each mouse IgG subclass and by peroxidase-conjugated
goat anti–rabbit IgG, following the same washing and incubation
steps. The assay was developed by adding 
 
o
 
-phenylenediamine di-
hydrochloride (OPD) as a substrate. Calibration was obtained by
referring to the binding of equivalent affinity anti-DNP IgG
 
1
 
,
IgG
 
2a
 
, IgG
 
2b
 
, and IgG
 
3
 
 mAbs to DNP-BSA–coated plates.
Spontaneous Ig concentrations were determined as described
(17). Plates were coated with goat anti–rabbit IgG followed by
rabbit antibodies specific for each mouse IgG subclass or for
mouse IgM (provided by J.-P. Coutelier, from our laboratory)
and a rat anti–mouse IgE (LO-ME-3; provided by H. Bazin). In-
cubations of serial dilutions of samples or standards were followed
by donkey antibodies specific for mouse IgG (or a rabbit anti–
mouse IgM), both conjugated to peroxidase, and for IgE deter-
mination a biotinylated rat anti–mouse IgE (LO-ME-2) plus
streptavidin-peroxidase (Sigma Chemical Co.) was used. Assays
were performed as described above for antigen-specific ELISA.
 
Analysis of Autoantibody Production.
 
Titration of rheumatoid
factor (RF)
 
1
 
 was performed in serum by latex agglutination as de-
scribed (18). RF titers were defined as the highest serum dilution
resulting in a 
 
.
 
10% agglutination of carboxylated polystyrene
particles (0.8-
 
m
 
m diameter; Rhône-Poulenc) coated as described
with purified mAbs obtained in our laboratory: IgG
 
2a
 
 (A7203C11.1)
or IgG
 
1
 
 (B8703B8.M). All sera were decomplemented before the
agglutination test by heating at 56
 
8
 
C for 30 min and centrifuged
for 5 min at 10,000 rpm. In brief, equal volumes (25 
 
m
 
l) of
 
1
 
Abbreviation used in this paper:
 
 RF, rheumatoid factor. 
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the agglutinator (serum samples, or standards: mAbs anti-IgG
 
2a
 
A7104B7.M and anti-IgG
 
1
 
 B101C1.M, both from 129/Sv mice
from our laboratory) and a 0.05% (wt/vol) latex suspension were
incubated for 30 min in a shaking water bath at 37
 
8
 
C. The agglu-
tination of IgG-coated particles in this mixture was measured by
the particle-counting immunoassay (PACIA), after 100
 
3
 
 dilu-
tion, by counting the residual nonagglutinated particles.
Antibromelain-treated RBC activity was measured as described
(19). Purified RBCs from FVB mice were obtained by retroor-
bital puncture on heparin and centrifugation on Lymphoprep
layer for 20 min at 1,700 rpm. RBCs were incubated as a 50%
suspension with bromelain (Sigma Chemical Co.) at a final con-
centration of 20 mg/ml in PBS for 45 min at 37
 
8
 
C, according to
the method of Cunningham (20). RBCs were washed three
times, and 25 
 
m
 
l of a suspension of 20 
 
3 
 
10
 
6
 
 cells/ml was incu-
bated with the same volume of serum dilutions for 30 min at
4
 
8
 
C. After washing and centrifugation, the bromelain-treated
RBCs were resuspended in Hank’s medium (with 3% decomple-
mented FCS and 0.01 M azide), incubated with rat mAb anti-
IgM LO-MM9 conjugated to fluorescein (5 
 
m
 
g/ml), and analyzed
on the FACScan™ apparatus. Results are given as the mean fluo-
rescence intensity for each sample.
Antithymocyte activity was detected by incubating 20 
 
m
 
l of a
suspension of FVB thymocytes (25 
 
3 
 
10
 
6
 
 cells/ml) with 50 
 
m
 
l of
diluted serum for 30 min at 4
 
8
 
C in microplates. After washing,
the resuspended thymocytes were treated, as described for bro-
melain-treated RBCs, with rat mAb anti-IgM LO-MM9 (pro-
vided by H. Bazin) conjugated to fluorescein (5 
 
m
 
g/ml). Results
are given as the mean fluorescence intensity for each sample as
measured on a FACScan™ apparatus.
 
Rosetting of B Cells with Bromelain-treated RBCs.
 
Peritoneal cell
suspensions were adjusted to 10
 
7
 
/ml with cold Hank’s medium
supplemented with 3% decomplemented FCS, before addition of
1/10 volume of a 10% bromelain-treated RBC suspension, as de-
scribed (21). Cells were centrifuged for 5 min at 1,600 rpm, and
resuspended on a roller at 4
 
8
 
C for 15 min. Enrichment of rosette-
forming cells was performed on a discontinuous Percoll gradient
composed of 2 ml of 70% solution for the lower layer and 2 ml of
30% solution for the upper layer. Cell mixtures were gently over-
laid on top of the gradient. The tubes were then centrifuged for
15 min at 2,000 rpm, and the pellets containing free RBCs and
rosettes were washed; RBCs were removed by NH
 
4
 
Cl treatment
followed by washes with Hank’s medium, and FACS
 
®
 
 staining
was performed as described above.
 
Statistical Analyses.
 
Statistical analyses were performed by
Mann-Whitney U statistical test for unpaired values using Instat
software.
 
Results
 
Increased Spontaneous and Specific Ig Production in IL-9
Transgenic Mice.
 
The spontaneous production of Ig was
analyzed in the progeny of five independent transgene-pos-
itive mice. As reported previously, IL-9 transgenic animals
have 
 
.
 
1 
 
m
 
g/ml of circulating IL-9 in the serum, whereas
IL-9 is undetectable (
 
,
 
100 pg/ml) in normal mice. In in-
dividuals of all transgenic lines bred under specific patho-
gen–free conditions, serum concentrations of IgM, IgG
 
1
 
,
IgG
 
2a
 
, IgG
 
2b
 
, IgG
 
3
 
, and IgE were significantly increased, as
shown for a representative line (Tg5) in Fig. 1 (
 
P
 
 , 
 
0.0001
for IgM, IgG
 
1
 
, IgG
 
2a
 
, IgG
 
2b
 
, and IgG
 
3
 
;
 
 P 
 
5 
 
0.0015 for IgE,
Mann-Whitney test). The most prominent were a 20- and
a 9-fold enhancement in IgG
 
1
 
 and IgE, respectively; IgM,
IgG
 
2a
 
, IgG
 
2b
 
, and IgG
 
3
 
 levels showed a 3–4-fold increase. A
similar picture was found with the other IL-9 transgenic
lines.
To investigate the influence of IL-9 on antibody produc-
tion against foreign antigens, wild-type control FVB and IL-9
transgenic mice were immunized with TNP-Ficoll or KLH.
The specific antibody response in the serum was measured
by ELISA 14 d after a primary injection or 14 d after a
boost injection. The result of such an immunization against
TNP-Ficoll is shown in Fig. 2. For every IgG subclass (IgG
 
1
 
,
IgG
 
2a
 
, IgG
 
2b
 
, and IgG
 
3
 
), IL-9 induced a modest (two- to
fivefold) but significant increase in TNP-specific antibodies
(
 
P
 
 , 
 
0.05 in the primary response for all IgG subclasses;
 
P 
 
, 
 
0.002 in the secondary response, Mann-Whitney test).
The results obtained with KLH were the same as with the
antigen (not shown).
 
Increased B Lymphocyte Numbers in IL-9 Transgenic Mice.
 
We next addressed the possibility that the increase of spon-
taneous Ig secretion could be associated with a modifica-
tion in B lymphocyte populations. Total cell counts and
FACS
 
®
 
 analysis with anti-IgM antibodies were first per-
formed with blood cells from control and Tg5 mice. As
shown in Table I, peripheral blood numbers of nucleated
Figure 1. Increase of spontaneous serum Ig isotypes in IL-9 transgenic
mice compared with FVB control mice. Ig isotypes are measured by
ELISA in sera of 20 individual female FVB and Tg5 12-wk-old mice, as
described in Materials and Methods. Results are expressed in mg/ml as
mean 6 SEM.1416 B-1 Lymphocyte Expansion in IL-9 Transgenic Mice
cells were tripled in transgenics, and B cell numbers rose
from 0.6 3 106/ml in control mice to 4.0 3 106/ml in
IL-9 transgenics, indicating a significant expansion of circu-
lating B cells. By contrast, in the spleen, the total number of
cells was only mildly increased (1.5–2-fold) in IL-9 trans-
genic mice, without preferential upregulation of B lympho-
cyte numbers. This observation indicates that splenic B lym-
phocytes are not specifically expanded in IL-9 transgenic
mice and that their number simply reflects a global spleen
enlargement. In line with these data, total cell and B lym-
phocyte numbers were only marginally increased in mesen-
teric lymph nodes of IL-9 transgenic animals.
To complete our analysis, we performed washouts of the
peritoneal and the pleuropericardial cavities. In these com-
partments, we observed a 7- and 22-fold increase, respec-
tively, in total numbers of cells in Tg5 compared with FVB
control mice. Labeling of these cells with anti-IgM anti-
bodies revealed an expansion for the B cell population in
IL-9 transgenic mice, by a factor of 15 and 56 for peritoneal
and pleuropericardial cells, respectively (Table I). These ob-
servations indicate that the absolute number of B cells in the
peritoneal and pleuropericardial cavities of an IL-9 transgenic
mouse is equivalent to 21% of the number of splenic B cells,
whereas this ratio is only 1.5% in a normal FVB mouse. Sim-
ilar observations were made with three other independent
IL-9 transgenic lines (data not shown).
Preferential B-1 Cell Expansion in the Peritoneal Cavity of
IL-9 Transgenic Mice. To determine in more detail the phe-
notype of the expanded B cell population in the peritoneal
cavity of IL-9 transgenics, FACS® analysis was performed
with anti-IgM, anti–Mac-1, and anti-CD5 antibodies. The
peritoneal and pleuropericardial cavities are indeed known
to be the preferential locations of B-1 lymphocytes, and
these three cell surface antigens allow us to discriminate the
major B lymphocyte subpopulations of the peritoneal cav-
ity (22, 23). B-1 lymphocytes can be distinguished from
conventional B cells (B-2 lymphocytes) by the expression
of an intermediate level of Mac-1, a marker expressed at
higher levels by macrophages. The result of FACS® stain-
Figure 2. Increase of specific IgG isotypes in serum of FVB and IL-9
transgenic mice immunized against TNP-Ficoll. Primary and secondary
responses were shown for nonimmunized mice and mice immunized
twice with 100 mg TNP-Ficoll without adjuvant. Antibody concentra-
tions are given as the mean 6 SEM for 10 individual measurements.
Table I. Total Cell and B Lymphocyte Numbers from Normal FVB and IL-9 Transgenic Mice
Peripheral blood cells Spleen cells Mesenteric lymph node cells Peritoneal cells Pleuropericardial cells
106/ml 106/mouse 106/mouse 106/mouse 106/mouse
FVB
Total cells 4.6 6 1.2 155 6 25 34 6 14 2.7 6 0.8 0.6 6 0.5
IgM1 0.6 6 0.2 59 6 10 8 6 3 0.8 6 0.2 0.13
Tg5
Total cells 12.2 6 3.4 233 6 37 46 6 6 19.5 6 4.8 13.2 6 4.7
IgM1 4.0 6 1.6 96 6 17 16 6 3 11.8 6 4.2 7.3
Cells were obtained as described in Materials and Methods, and numbers of sIgM1 cells were determined by FACS® analysis. Numbers of cells per
mouse are given as the mean for groups of 5–10 individuals (6SD), except for the sIgM1 pleuropericardial cells, for which a pool of cells from five
animals was analyzed. Number of blood sIgM1 is given as the mean per milliliter of blood.1417 Vink et al.
ing of peritoneal cells is shown in Fig. 3. This confirmed the
predominant expansion of IgM1 cells in IL-9 transgenic
mice. Interestingly, these IgM1 cells expressed an interme-
diate level of Mac-1, thereby corresponding to the B-1 lin-
eage. Although in normal mice the majority of peritoneal
cells consisted of macrophages that express high levels of
Mac-1 and no IgM, most of the IL-9 transgenic peritoneal
cells consisted of B-1 lymphocytes with expression of both
surface IgM and Mac-1 (Fig. 3 A).
Within B-1 cells, two subpopulations are defined on the
basis of CD5 expression: B-1a lymphocytes are IgM1Mac-
11CD51, and B-1b lymphocytes are IgM1Mac-11CD52.
A three-color labeling of peritoneal cells showed that both
populations of B-1 lymphocytes were expanded, but that
the major increase in the peritoneal populations concerned
the B-1b cells (IgM1Mac-11CD52) in IL-9 transgenics com-
pared with FVB control mice (Fig. 3 B, and Table II).
Fig. 4 shows the kinetics of accumulation of peritoneal
cells in two IL-9 transgenic lines (Tg5 and Tg54). At 3 wk
of age, there was already a significant difference between
the number of peritoneal cells found in the peritoneal cav-
ity of transgenic mice compared with control mice (P ,
0.008, Mann-Whitney test). This difference reached five-
to sevenfold after 6–12 wk, and peritoneal numbers re-
mained stable at this level throughout the life of the indi-
viduals. Animals of .18 mo presented a similarly enlarged
cell population as younger individuals (data not shown). In
aging FVB control mice, peritoneal cell numbers increased
slightly compared with young individuals.
B-1 Cell Expansion in Other Lymphoid Compartments of IL-9
Transgenic Mice. In common strains, the B-1 cell popula-
tion constitutes a predominant fraction of the peritoneal and
pleuropericardial B cell population, but is rare in spleen and
lymph nodes and absent in the peripheral blood lympho-
cytes of adult animals. We checked the other B cell com-
partments for the presence of B-1 cells by double labeling,
with anti-IgM and anti–Mac-1 antibodies, of cells from dif-
ferent locations in IL-9 transgenic and control animals.
As shown in Fig. 5, in every location where we found an
increase in B cell numbers (peritoneal and pleuropericardial
cavities, and blood), IgM1Mac-11 cells were clearly ex-
panded. This is particularly remarkable in blood, where
IgM1Mac-11 cells were completely absent in normal mice
but represented up to 4.1% of total blood cells and 15% of
blood B cells in IL-9 transgenic mice. In spleen, although
Mac-1 staining of IL-9 transgenic B cells was too weak to
clearly distinguish a positive and negative population, in-
creased Mac-1 staining was observed in IgM1 cells (mean
fluorescence intensity 41 in Tg5 vs. 25 in FVB mice), sug-
gesting the presence of Mac-11 B cells in Tg5 spleen.
Peritoneal Cell Expansion Induced by Exogenous IL-9 in
Normal Mice. The IL-9 transgenic mice used in this study
Figure 3. Three-color FACS® staining of FVB and IL-9 transgenic
peritoneal cells. Peritoneal cells were labeled as described in Materials and
Methods with anti–Mac-1, anti-IgM, and anti-CD5. Results of analysis
of 5 3 104 cells are shown for one representative individual of FVB and
Tg5 mice. (A) Mac-1/IgM labeling. (B) CD5 labeling of IgM1Mac-11
cells. Percentages in B correspond to the proportion of CD51 cells among
IgM1Mac-11 cells.
Table II. Numbers of B-1a (IgM1Mac-11CD51) and B-1b 
(IgM1Mac-11CD52) Cells in Peritoneal Populations of FVB 
Normal and Tg5 Mice
B-1a B-1b
106/mouse 106/mouse
FVB 0.3 6 0.1 0.3 6 0.1
Tg5 1.6 6 0.8* 5.3 6 2.0*
Washouts of peritoneal cavities were performed for 10 12-wk-old
mice, and cells were three color labeled with anti–Mac-1, anti-IgM,
and anti-CD5 as described in Materials and Methods. Results are ex-
pressed as millions of cells per mouse (mean 6 SD). *P , 0.0001,
Mann-Whitney test. In Tg5 animals, B-1b cells outnumbered B-1a
cells (P , 0.0001, Mann-Whitney test).
Figure 4. Kinetics of accumulation of peritoneal cells in IL-9 trans-
genic (Tg5 and Tg54) and FVB mice. Peritoneal cells were counted from
groups of 5 mice of 3, 6, 9, and 12 wk of age and 10 mice of 24 and
48 wk of age. Results are expressed as cell numbers per mouse 6 SD.
The difference between transgenic and control mice was statistically sig-
nificant for all ages tested (Mann-Whitney test).1418 B-1 Lymphocyte Expansion in IL-9 Transgenic Mice
show elevated levels of this cytokine before birth (Renauld,
J.-C., unpublished data). To assess whether the effect of IL-9
on B-1 lymphocytes required early and prolonged overex-
pression, we administered, to 8-wk-old FVB mice, daily
intraperitoneal injections of mouse recombinant IL-9
(1  mg/d/mouse) for 1, 3, 7, 14, or 21 d. Total counts of
peritoneal cells are given in Fig. 6. Seven injections of IL-9
were sufficient to observe a twofold increase in peritoneal
cell numbers. Seven additional injections allowed a further
increase to reach a plateau after 2–3 wk of daily injections
(P , 0.008, Mann-Whitney test).
Double labeling with anti-IgM and anti–Mac-1 was per-
formed to confirm B-1 cell expansion in mice that received
21 daily injections of 1 mg of IL-9. Fig. 7 shows the preferen-
tial increase of the B-1 population in treated FVB mice as
well as in another strain, C57BL/6. Total numbers of IgM1
Mac-11 cells increased by a factor of 6.8 for FVB (P 5 0.016,
Mann-Whitney test) and 3.3 for C57BL/6 mice (P 5 0.05).
By contrast, IgM1Mac-12 (B-2) cells were not significantly
affected by IL-9.
IL-9 Mediates an Increase in the Peritoneal B-1 Population in
the Absence of IL-5. Many reports, including the analysis
of IL-5 transgenic mice, point to IL-5 as a key factor for
the B-1 population (24–26). Although IL-5 is a potent
growth factor for B-1 cells, it does not seem to be indis-
pensable, since IL-5 knockout mice show a delay in B-1
Figure 5. Mac-1/IgM FACS® staining of cells from different locations
in FVB and IL-9 transgenic mice. Cells obtained from peripheral blood,
spleen, mesenteric lymph nodes, and peritoneal and pleuropericardial cav-
ities were double stained as described in Materials and Methods. Labeling
was shown as a contour plot obtained from analysis of 104 cells of one
representative mouse for control or transgenic mice.
Figure 6. Accumulation of peritoneal cells upon daily injection of IL-9
to FVB control mice. Groups of three to five mice were injected daily
with 1 mg IL-9 or PBS as described in Materials and Methods. The num-
bers of cells/mouse are shown as mean 6 SD. The difference between
IL-9–injected and PBS-injected animals was statistically significant for 14
and 21 injections (P , 0.008, Mann-Whitney test).
Figure 7. Preferential accumulation of peritoneal B-1 (IgM1Mac-11)
lymphocytes in mice injected with IL-9. Numbers of B-1 lymphocytes
are shown for FVB and C57BL/6 mice injected daily with PBS or with
IL-9 for 21 d. Double labeling of cells allowed us to differentiate B-1
(IgM1Mac-11) and B-2 (IgM1Mac-12) lymphocytes. The numbers of
cells/mouse are shown as mean 6 SD for a group of five individuals.1419 Vink et al.
population development and a weak reduction of perito-
neal B-1 cell numbers in adults (14, 27).
To assess whether the activity of IL-9 is mediated by IL-5
or whether IL-9 can contribute to the development of B-1
cells in the absence of IL-5, we crossed IL-5–deficient mice
with IL-9 transgenics (Tg5 or Tg54), and F1 mice were
backcrossed with IL-5–deficient mice. Thus, 50% of the F2
hybrids have one copy of the normal IL-5 gene, and 50% of
the mice express the IL-9 transgene. We performed B-1 cell
numbering and determination by three-color analysis of the
ratio between the B-1a (IgM1Mac-11CD51) and B-1b
(IgM1Mac-11CD52) cells in the peritoneal washouts of in-
dividuals belonging to the four groups obtained.
In F2 mice having one copy of the normal IL-5 gene,
overexpression of IL-9 resulted in a significant increase in
the number of the B-1 population, and this expansion con-
cerned mainly the B-1b population, as expected from the
results described above (Fig. 8 A). Interestingly, IL-9 had
the same effect on the number of CD52 B-1 cells in the
IL-5–deficient animals (Fig. 8 B). Similar results were ob-
tained with Tg54 hybrids (not shown). In these experi-
ments, the IL-5 deficiency resulted in a 50% decrease in B-1
numbers, but irrespectively of IL-9 expression. Taken to-
gether, these observations demonstrate that, although IL-5
plays a role in B-1 cell development, it does not mediate
the activity of IL-9 on this cell type.
Preferential Expression of the IL-9 Receptor by Peritoneal B-1
Cells. A simple explanation for the expansion of B-1 cells
by IL-9 could be a B-1–specific expression of the IL-9 re-
ceptor.  To analyze IL-9 receptor expression, peritoneal
cells from normal FVB mice were stained with a fusion
protein consisting of IL-9 fused to the Fc fragment of
mouse IgG3. The binding of this protein was detected by
FACS®, using a secondary antibody specific for IgG3. The
specificity of the binding was demonstrated by its reversion
in the presence of an excess of IL-9. As shown in Fig. 9 A,
a fraction (z34%) of peritoneal IgM1Mac-11 cells were
stained with this fusion protein. The labeling with anti-
Figure 8. Accumulation of B-1b (IgM1Mac-11CD52) cells in IL-9
transgenic mice normal for IL-5 (A) or in mice deficient in IL-5 (B).
Three-color staining of peritoneal cells for F2 hybrids was performed for
groups of five individuals. Results are expressed in 106 cells/mouse, mean 6
SEM, and are given for B-1a (IgM1Mac-11CD51) and B-1b cells
(IgM1Mac-11CD52). *P , 0.05, Mann-Whitney test. tg, transgenic.
Figure 9. Expression of the IL-9 receptor (IL-9R) by peritoneal B-1
cells from normal FVB mice. Labeling was shown as a contour plot ob-
tained by analysis of 104 cells from a pool of 10 individual mice. (A) Peri-
toneal cells from normal FVB mice were stained with the mIL-9–Ig fu-
sion protein and anti-IgM (1 and 2), anti–Mac-1 (3 and 4), or anti-CD5
(5 and 6) antibodies as described in Materials and Methods. Controls con-
sisted of cells labeled in the presence of an excess of free IL-9, as a com-
petitor. (B) Splenic cells were similarly stained with the mIL-9–Ig fusion
protein and anti-IgM (7 and 8) antibodies.1420 B-1 Lymphocyte Expansion in IL-9 Transgenic Mice
CD5 antibodies showed that both B-1a and B-1b popula-
tions expressed the IL-9 receptor. By contrast, the IL-9 re-
ceptor was barely detectable at the surface of IgM1 B cells
from the spleen (Fig. 9 B).
Distinct Specificities between B-1a and B-1b Cells in IL-9
Transgenic Mice. Numerous studies have demonstrated a
role for B-1 cells in the secretion of autoantibodies such as
anti-RBC, antithymocyte, or RF (28–30). In particular,
IL-5 transgenic mice showed elevated levels of anti-DNA
antibodies in the serum, concomitant with the increased
frequency of B-1 cells (25). The best-described specificity
of the autoantibodies secreted by B-1 cells is directed
against an antigen presented by RBCs treated by the pro-
teolytic enzyme bromelain.
The concentrations of autoantibodies were measured in
the serum of Tg5 or FVB mice that either had or had not
received three in vivo injections of LPS, since it was
known that this treatment upregulates autoantibody pro-
duction (31). As shown in Fig. 10, we failed to detect any
difference between IL-9 transgenic and FVB control mice
concerning basal levels of anti-IgG1 or anti-IgG2a RFs, anti-
thymocyte antibodies, or antibromelain-treated RBC au-
toantibodies. As expected, LPS injection increased the pro-
duction of these antibodies but with the same intensity in
IL-9 transgenic mice as in normal mice.
Antibromelain-treated RBC specificity is considered to
be a unique characteristic of a significant proportion of B-1
cells (19). Thus, the lack of difference in anti-RBC anti-
body production between IL-9 transgenic and FVB mice,
even after LPS induction, suggests that IL-9–induced B-1
cells have a distinct specificity compared with the classical
B-1 population. To check this hypothesis, we analyzed di-
rectly the specificity of peritoneal B cells by testing their
ability to form rosettes with bromelain-treated RBCs.
Peritoneal cells from FVB or Tg5 mice were incubated
with bromelain-treated RBCs, and rosetting cells were sep-
arated from free peritoneocytes on a Ficoll layer. The re-
sulting RBC-specific B cells were subsequently stained
with anti–Mac-1 and anti-CD5 fluorescent antibodies. The
results of two independent experiments are shown in Table
III. In both FVB and IL-9 transgenic mice, enrichment in
RBC-specific cells was paralleled by an increase in the pro-
portion of CD51Mac-11 cells, reflecting the high frequency
of anti-RBC lymphocytes in this population. In IL-9 trans-
genic mice, selection of anti-RBC resulted in a significant
drop in the percentage of Mac-11CD52 cells, indicating
that this specificity is much less frequent in this population.
Thus, this experiment demonstrates that IL-9–induced
B-1b cells do not exhibit the same autoimmune specificity
as B-1a cells.
Discussion
In this paper, we report that IL-9 induces a specific ex-
pansion of B-1 lymphocytes in vivo. In normal mice, this
population constitutes only 1% of the total B cells and re-
sides mainly in the peritoneal and pleuropericardial cavities.
In IL-9 transgenics, we found a 15–20-fold increase in B-1
cell numbers at these locations. In addition, although B-1
lymphocytes were absent in the blood of normal animals,
they represented up to 15% of blood B cells of IL-9 trans-
genics, based on Mac-1 and IgM expression.
Another characteristic of the peritoneal B-1 population
found in IL-9 transgenics is the ratio between B-1a and B-1b
cells in favor of the B-1b subset, contrasting with the more
balanced situation between B-1a and B-1b subpopulations
Figure 10. Autoantibody concentrations in mice treated with LPS in
vivo. Mice were treated three times at 1-wk intervals with PBS or 50 mg
LPS i.p., and sera were taken 1 wk after the third injection. Sera were
tested for concentrations of anti-IgG1 or anti-IgG2a RF as described in
Materials and Methods. Values were given for each individual as an arbi-
trary titer giving 10% agglutination. Sera were also tested for antithymo-
cyte activity and antibromelain-treated RBCs (Anti-brRBC). Autoanti-
bodies fixed on thymocytes and RBCs were detected by staining with a
fluorescent anti-IgM; results are given for each individual (three to four
controls versus six LPS-treated mice) as mean fluorescence intensity.
Table III. Enrichment of B-1a Lymphocytes in Peritoneal 
Rosette-forming Cells from FVB and Tg5 Mice
FVB Tg5
Percent
in total
Percent
in RFCs
Percent
in total
Percent
in RFCs
Experiment 1
B-1a 14 57 16 63
B-1b 18 21 52 24
Experiment 2
B-1a 9 57 16 33
B-1b 11 10 50 18
Peritoneal cells from FVB and Tg5 that formed rosettes with brome-
lain-treated RBCs were labeled with anti–Mac-1 and anti-CD5 as de-
scribed in Materials and Methods. Results of two different experiments
are shown as percentages of Mac-11CD51 (B-1a) and Mac-11CD52
(B-1b) in total cells and in rosette-forming cells (RFCs).1421 Vink et al.
found in the FVB background. In addition, the B-1b ex-
pansion in IL-9 transgenic mice might be underestimated,
since B-1 cells are supposed to lose Mac-1 in the spleen
(22, 23). Therefore, additional criteria are critically needed
to study the B-1b population in spleen and lymph nodes.
In most models, expansion of the B-1 population is asso-
ciated with high levels of autoantibody secretion. In NZB
and (NZB 3 NZW)F1 mice, CD51 B cells accumulate in
the peritoneal cavity and in the spleen, and produce auto-
antibodies against single-stranded DNA, thymocytes, or
bromelain-treated mouse erythrocytes (28, 32). In another
in vivo model, increased CD19 expression also resulted in
an expansion of CD51 B cells within the peritoneum and
spleen, correlating with high levels of anti-DNA antibodies
and RF (33). Other models resulting from mutation in the
SHP1 gene (34) or targeting of genes involved in signal
transduction, such as Btk (35) or vav (36, 37), also support
the link between B-1 cell development and levels of auto-
antibodies.
In the IL-9 transgenics, we failed to detect any increase
in the production of RF, antithymocyte, or antibromelain-
treated RBC antibodies. In particular, antibromelain-treated
RBC specificity was mainly found in peritoneal CD51 B-1
cells, as demonstrated in the experiments with rosette-
forming cells with bromelain-treated RBCs. This is in line
with a previous report indicating that the antibromelain-
treated RBC specificity is restricted to CD51 cells (38).
However, we cannot formally exclude that the activity of
IL-9 could be selective within the B-1b population and
that expanded cells derive from a subset of B-1b cells
which has properties distinct from B-1b cells from normal
animals.
In our model, IL-9 production induced an increase in all
spontaneous Ig isotypes. The most prominent were a 20-
and a 9-fold enhancement in IgG1 and IgE, respectively;
IgM, IgG2a, IgG2b, and IgG3 levels showed only a 3–4-fold
increase. This is again different from other models with ex-
pansion of B-1 cells, such as mice homozygous for the via-
ble mutation motheaten mev, where all B cells are CD51,
and IgM, IgG3, and IgA serum concentrations are 10–50
times greater than in control mice but IgG1 levels remain
unaffected (39). This difference might also be related to the
fact that B-1b cells are more expanded than B-1a cells in
IL-9 transgenic mice. Although conventional B cells did
not seem to express the IL-9 receptor to the same extent as
B-1 cells and were not expanded in response to IL-9, we
could not rule out the possibility that they also contribute
to this increase in Ig production. For example, other IL-
9–responsive cells, such as mast cells, T cells, or even the
B-1 cells, could mediate an indirect effect of IL-9 on con-
ventional B cells through the production of other cyto-
kines. In this respect, B-1 cells have been reported to be an
important source of IL-10 (40). However, we failed to de-
tect any increase in IL-10 production in IL-9 transgenic
mice (our unpublished data).
The observation that B-1 cell numbers were increased
by IL-9 in the absence of IL-5 ruled out the possibility that
the effect of IL-9 is mediated by this cytokine. IL-5 is a po-
tent activator of B-1 cells, and mice overexpressing IL-5
are also characterized by an increase in B-1 cells. However,
in contrast to IL-9 transgenics, the cellular expansion ex-
clusively concerned the B-1a population of the spleen (25).
The serum IgG1 levels were not modified, but IgM and
IgA levels were increased by eight- and fourfold, respec-
tively, in IL-5 transgenics.
Surprisingly, the IL-9 receptor appeared to be expressed
at similar levels in many normal B-1a and B-1b lympho-
cytes, whereas the B-1b population is preferentially ex-
panded in vivo. These data suggest that distinct homeostasis
mechanisms control these subpopulations. The fact that the
number of CD51 B cells is endogenously controlled has
been reported, but the mechanisms remain unclear (41). In
addition, despite the high level of IL-9 receptor at the sur-
face of B-1 cells, we failed to demonstrate in vitro prolifer-
ative responses of these cells to IL-9 (our unpublished data),
suggesting that the actual role of IL-9 on B-1 cells might be
related to other features, such as differentiation or survival.
In this report, the increase of antigen-specific Ig concen-
trations in TNP-Ficoll– or KLH-immunized IL-9 transgenic
mice and the specific expansion of the B-1 populations sug-
gest that these cells could actively participate in the immune
response against various proteic antigens. Future experiments
will be needed to determine their actual role in more physi-
ological responses and particularly in allergic responses, in
which a role for IL-9 was recently demonstrated (7).
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